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Recent studies have shown that administering the aromatase inhibitor exemestane after 2–3 years of tamoxifen therapy significantly
improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen
treatment. Although many of the adverse effects associated with exemestane and tamoxifen have been analysed, there are no
comparative data concerning body weight and body composition. The aim of this randomised study was to evaluate the longitudinal
changes in body composition and lipid profiles in postmenopausal women switched from tamoxifen to exemestane. In total, 60
overweight or obese postmenopausal patients were enrolled. Their anthropometric data, body composition, including fat mass (FM)
and fat-free mass (FFM), and lipid profiles, caloric intake and physical activity were assessed 1 week before randomisation, and 6 and
12 months later. In all, 55 patients (27 on tamoxifen and 28 on exemestane) completed the 1-year study period. Fat mass had
significantly decreased by month 12 in the exemestane, but not in the tamoxifen group; the between-group difference was statistically
significant (Po0.01). The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group; the
between-group difference was statistically significant (Po0.05). Triglycerides and high-density lipoprotein cholesterol significantly
decreased (Po0.01; Po0.05), and low-density lipoprotein cholesterol significantly increased (Po0.01) in the exemestane group at
the end of the 1-year study period. Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2
years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body
composition.
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Tamoxifen is currently used to treat all stages of oestrogen
receptor-positive breast cancer and, in the adjuvant setting, has
substantial benefits in terms of disease-free and overall survival
(Early Breast Cancer Trialists’ Collaborative Group, 1992).
The major symptoms attributable to tamoxifen therapy are hot
flushes, sweating and vaginal discharges. Although serious adverse
medical effects are rare, women are often concerned about some of
the risks of tamoxifen therapy, such as blood clots, strokes and
endometrial cancer (Meier and Jick, 1998; Ganz, 2001). Moreover,
they have often reported a range of events attributed to tamoxifen
therapy, including weight gain (Hoskin et al, 1992; Rose et al,
1993). A checklist-based study of patients on endocrine therapy
found that weight gain was a common problem in patients on
tamoxifen (Malinovszky et al, 2004), but the results of large-scale,
randomised clinical trials such as NSABP-B14 and NSABP-P1
suggest that adjuvant tamoxifen therapy is not associated with an
increased risk of weight gain, although it must be pointed out that
they considered only body weight and not body composition
(Fisher et al, 1989, 1998). Nevertheless, adult weight gain is largely
reflected in increased body fat, which may be more suitable for
assessing adiposity and its metabolic consequences than body
weight or the body mass index (BMI), which reflect both lean and
fat body mass (Abu-Abid et al, 2002).
The negative effects of excess body weight and fat mass (FM) on
the recurrence of breast cancer, and the survival of both pre- and
postmenopausal women, has recently been underlined (Daling
et al, 2001).
Third-generation aromatase inhibitors, which are considered
a new development in the endocrine treatment of oestrogen
receptor-positive breast cancer in postmenopausal women,
prevent the conversion of adrenal androgens into oestrogens by
inhibiting the aromatase of the cytochrome P450-dependent
enzyme that is responsible for the majority of oestrogen
production in postmenopausal women as well as in men (Smith
and Dowsett, 2003).
One of the three newest aromatase inhibitors is exemestane,
whose irreversible binding to the aromatase enzyme causes
permanent inactivation even after the drug is cleared from the
circulation (Goss and Strasser, 2001). Recent findings have shown
that, in comparison with standard 5-year tamoxifen therapy, the
administration of exemestane after 2–3 years of tamoxifen
significantly improves disease-free survival in postmenopausal Received 10 April 2006; revised 14 June 2006; accepted 14 June 2006
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Although many of the adverse effects associated with tamoxifen
and exemestane have been analysed, there are no comparative data
concerning their effects on body composition and body weight;
furthermore, there are few published data concerning the impact
of adjuvant exemestane therapy on lipid profiles (Atalay et al,
2004; Markopoulos et al, 2005). The aim of this study was to
evaluate the changes in the body composition and lipid profiles of
postmenopausal women switched from tamoxifen to exemestane.
PATIENTS AND METHODS
Eligibility criteria
The study was approved by our Institutional Review Board, and all
of the patients gave their written informed consent.
The eligible patients were postmenopausal oestrogen receptor-
positive women with resected breast cancer aged less than 75 years,
who had a BMI of 25–35 (weight(kg)/height(m)
2) and had received
at least 2 years’ adjuvant tamoxifen treatment. Postmenopausal
status was defined as an age of 55 years or more with amenorrhea
for more than 2 years, or amenorrhea for more than 1 year at the
time of diagnosis. The exclusion criteria were any evidence of a
local relapse or distant metastasis, clinical signs of severe
osteoporosis, the use of medications that could affect lipid levels,
or the presence of serious medical conditions that could alter food
absorption or prognosis. The subjects were randomised using a
computer-generated sequence; the person responsible for the
randomisation and the people making the study measurements
were blinded. The study was not nested in a larger randomised
trial.
In total, 60 patients met the eligibility criteria and were
randomised to continue tamoxifen 20mgday
 1 (n¼30) or to
switch to exemestane 25mgday
 1 (n¼30). The two groups were
well balanced in terms of their main baseline characteristics,
including height, weight and BMI (Table 1). All of the enrolled
women were overweight or obese.
Measurements
The patients’ anthropometric data (including height, weight and
BMI), body composition, lipid profiles, physical activity, food
intake and quality of life (QOL) were assessed 1 week before
randomisation, and after 6 and 12 months of treatment. Weight
was measured using a balance beam scale after an overnight fast.
Lipid metabolism
Fasting venous blood samples were drawn at all visits in order to
assess the levels of total cholesterol (TC), triglycerides (TG) and
high- and low-density lipoprotein cholesterol (HDL-C and LDL-C),
which except for LDL-C (calculated using Friedwald’s formula)
were measured by means of colorimetry (Autoanalyzer, Menarini,
Italy). The intra- and interassay coefficients of variation in our
Institution are, respectively, 1.8 and 3.9% for TC, 1.7 and 3.0% for
TG, and 2.0 and 3.0% for HDL-C.
All of the individual samples were stored at  801C until analysis
when they were assayed using one batch of reagent.
Body composition
Body composition was evaluated by means of a single, whole-
body, dual-energy X-ray absorptiometry scan made using
a QDR 4500 Hologic machine (DXA Hologic Inc., Waltham, MA,
USA), and the results were used to derive FM, and fat-free
mass (FFM).
The DXA measurements were of high quality. Although the
method has good long-term stability and precision, consistent
performance was further ensured by means of a daily quality
control scan using a known standard (the manufacturer’s
phantom).
QOL assessment
In order to assess their health-related QOL, all of the patients were
asked to complete the European Organisation for Research and
Treatment of Cancer (EORTC) core questionnaire (EORTC/QLQ-
C30) at trial entry, and after 6 and 12 months (Aaronson et al,
1993). The questionnaire consists of 30 items covering general
physical symptoms and function, fatigue/malaise, and social and
emotional functioning: higher function scores indicate better
functioning, whereas higher symptom scores indicate worse
symptoms.
During the QOL interview, the women provided information
concerning exercise (recorded as the number of hours/week
devoted to physical activity) and food intake, which was measured
by means of a food frequency questionnaire translated into Italian
(Sallis et al, 1985; Block et al, 1986).
Statistical analysis
Assuming an increase of about 15% in serum LDL-C in women
switched from tamoxifen to exemestane, a randomised design
required 30 patients per group to verify a statistical significant
difference in this parameter with an a of 0.05 and a b of 0.80.
Analysis of variance for paired data was used to evaluate the
within-group variations in all of the parameters, and analysis of
variance for unpaired data to evaluate between-group differences
after having calculated the percentage changes at each visit.
Nonparametric tests were used as appropriate. A P-value of o0.05
was considered statistically significant for all of the tests, which
were made using SPSS 10.1 statistical software.
Table 1 Baseline characteristics of the study population
Tamoxifen (n¼27) Exemestane (n¼28)
Age (years) 61.1572.74 61.8974.45
Tumour stage
T1 46% 38%
T2 36% 40%
T3 18% 22%
Node status
N+(1–3) 21% 18%
N+(44) 8% 15%
Negative 71% 67%
Estrogen receptor status
Positive 100% 100%
Negative 0 0
Progesteron receptor status
Positive 72% 65%
Negative 28% 35%
Primary treatment
Mastectomy 61% 54%
Radiotherapy 42% 51%
Chemotherapy 24% 27%
Height, cm (mean7s.d.) 156.472.06 155.9671.92
Weight, kg (mean7s.d.) 69.7576.21 69.8877.58
BMI, kg/m
2 (mean7s.d.) 28.9771.88 29.1772.12
BMI¼body mass index.
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Of the 60 enrolled patients, 55 (27 on tamoxifen and 28 on
exemestane) completed the 1-year study period, three were lost to
follow-up, and two had concomitant diseases unrelated to the
study drugs (not cardiovascular complications). Table 1 shows the
characteristics of the 55 study completers included in the analysis.
Table 2 shows the mean (7s.d.) weight, caloric intake and
physical activity in the two groups at baseline, and after 6 and 12
months. Weight remained unchanged in the tamoxifen group
(69.7576.21kg at baseline and 69.1777.33kg at month 12), but
decreased in the exemestane group (69.8877.58kg at baseline and
67.8977.45kg at month 12; P¼0.06). The questionnaire data
showed no statistically significant differences in baseline caloric
intake or physical activity between the tamoxifen and exemestane
group, and no statistically significant changes were observed in
either group after six and 12 months.
Fat mass had significantly decreased by month 12 in the
exemestane group (Po0.01) but not in the tamoxifen group; the
between-group difference was statistically significant (Po0.01)
(Figure 1A): The FFM/FM ratio significantly increased by month
12 in the exemestane group (Po0.01) but not in the tamoxifen
group; the between-group difference was statistically significant
(Po0.05) (Figure 1B).
There were no statistically significant changes in the lipid
profiles of the patients treated with tamoxifen (Table 3). In the
exemestane group, HDL-C decreased by 9.1% at month 6 and by
12.0% at month 12 when the difference became statistically
significant (Po0.05), LDL-C significantly increased by 14.8% at
month 6 and 16.5% at month 12 (Po0.01), and TG decreased by
12.1% at month 6 and 16.9% at month 12 (Po0.01). The between-
group differences were statistically significant only for LDL-C
(Po0.05).
The comparison of the linearly transformed mean values
of the EORTC-QLQ-C30 data was performed: the very similar
global health status (P¼0.9) and global QOL scores (P¼0.9)
of the two groups indicated that there were no statistically
significant differences in their baseline QOL. In comparison with
baseline, none of the P-values in the functional and symptom
scales showed any clear between-group trend at month 6 but,
at month 12, there was a trend toward improved physical
functioning, global health status and global QOL scores in the
exemestane group; the between-group difference was not statisti-
cally significant.
DISCUSSION
Tamoxifen has long been the gold standard therapy for
postmenopausal women with hormone receptor-positive breast
cancer but, although the drug is generally well tolerated, its
prolonged use may be associated with various side effects,
including gynecological and thromboembolic complications
(Fisher et al, 1998). Moreover, a few studies have reported some
changes in body weight (especially weight gains) in women with
resected breast cancer receiving adjuvant treatment including
tamoxifen (Camoriano et al, 1990; Chlebowski et al, 2002;
Malinovszky et al, 2004).
The present study suggests, for the first time, that switching
overweight or obese patients to adjuvant treatment with exemes-
tane after at least 2 years of tamoxifen therapy is associated with a
significant decrease in FM (Figure 1), with no statistical significant
difference in body weight (Table 2). It must be remembered that
the precise pathophysiological mechanisms of body weight
changes remain unclear in many patients and that, as body weight
is determined by an interplay of caloric intake, activity level and
metabolic rate, significant alterations in any of these factors may
lead to weight loss or gain (Levine et al, 1991; Goodwin et al, 1998).
However, we observed no statistically significant differences in
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scaloric intake or physical activity between our two randomised
groups during the study period (Table 2).
One possible explanation of our findings is that the pharmaco-
logical properties of exemestane are different from those of
tamoxifen. The effects of tamoxifen on the human body vary and
can be characterised as a mixture of oestrogenic and anti-
oestrogenic properties, whereas exemestane inhibits in vivo
aromatisation by about 98% and has no partial agonist activity,
thus leading to a profound decrease in serum oestrogen levels
(Furr and Jordan, 1984; Geisler et al, 1998). Two-thirds of breast
tumours are oestrogen-dependent, and aromatase inhibitors can
help block the growth of these tumours by lowering the amount of
oestrogen in the body (Yeu and Santen, 1996). As it is known that
exemestane and the other aromatase inhibitors reduce circulating
oestrogen levels, and that oestrogens have direct effects on
adipocytes and the other cellular constituents of adipose tissue,
there may be an association between exemestane use, reduced
circulating oestrogen levels and body weight changes (Siiteri, 1987;
Selby, 1990; Hankinson et al, 1995). However, if such an
association exists, our data do not offer any evidence as to
whether the expected decrease in oestrogen levels was the cause or
effect of body weight changes.
The use of exemestane may also influence appetite, but our QoL
questionnaire did not reveal any statistically significant changes in
appetite in our study population.
Another intriguing point is the effect of tamoxifen and
exemestane on the lipid profiles of postmenopausal women. It
has long been known that oestrogens lower serum cholesterol, and
that the agonist activity of the selective oestrogen-receptor
modulator tamoxifen has protective effects on lipid profiles (Love
et al, 1990). Nevertheless, it has recently been suggested that
women receiving aromatase inhibitors for breast cancer preven-
tion may be at increased risk of cardiovascular diseases, because
the oestrogen-lowering effects of such drugs may have adverse
effects on blood lipids (Baum et al, 2003; Goss et al, 2003; Atalay
et al, 2004; Esteva and Hortobagyi, 2006; Markopoulos et al, 2005).
Our data showed a significant increase in LDL-C in the patients
P
e
r
c
e
n
t
 
c
h
a
n
g
e
s
 
(
%
)
 
i
n
 
F
M
 
*
–12
–10
–8
–6
–4
–2
0
2
§
6 months 12 months
–2
0
2
4
6
8
10
12
14
Exemestane Tamoxifen
P
e
r
c
e
n
t
 
c
h
a
n
g
e
s
 
(
%
)
i
n
 
F
F
M
/
F
M
*
#
6 months 12 months
A
B
Figure 1 Percentage changes in FM (A) and the FFM/FM ratio (B) in the
exemestane and tamoxifen groups after 6 and 12 months (*Po0.01 vs
baseline; #Po0.05, ybetween groups).
T
a
b
l
e
3
L
i
p
i
d
e
p
r
o
f
i
l
e
:
m
e
a
n
v
a
l
u
e
s
(
7
s
.
d
.
)
o
n
t
a
m
o
x
i
f
e
n
a
n
d
e
x
e
m
e
s
t
a
n
e
t
h
e
r
a
p
y
T
a
m
o
x
i
f
e
n
E
x
e
m
e
s
t
a
n
e
B
a
s
e
l
i
n
e
6
t
h
m
o
n
t
h
1
2
t
h
m
o
n
t
h
B
a
s
e
l
i
n
e
6
t
h
m
o
n
t
h
1
2
t
h
m
o
n
t
h
T
C
(
m
g
d
l
 
1
)
2
1
5
.
1
2
7
1
0
.
0
1
(
C
I
:
2
1
1
.
3
4
–
2
1
8
.
9
0
)
2
1
6
.
2
3
7
1
0
.
4
4
(
C
I
:
2
1
2
.
2
9
–
2
2
0
.
1
7
)
2
1
5
.
3
2
7
1
1
.
2
1
(
C
I
:
2
1
1
.
0
9
–
2
1
9
.
5
5
)
2
1
5
.
6
8
7
9
.
3
1
(
C
I
:
2
1
2
.
2
3
–
2
1
9
.
1
3
)
2
2
4
.
2
7
7
1
3
.
3
3
(
C
I
:
2
1
9
.
3
3
–
2
2
9
.
2
1
)
2
2
4
.
1
7
7
1
2
.
8
3
(
C
I
:
2
1
9
.
4
2
–
2
2
8
.
9
2
)
H
D
L
-
C
(
m
g
d
l
 
1
)
5
8
.
6
2
7
6
.
1
7
(
C
I
:
5
6
.
2
9
–
6
0
.
9
5
)
5
8
.
2
2
7
8
.
7
7
(
C
I
:
5
4
.
9
1
–
6
1
.
5
3
)
5
7
.
9
8
7
8
.
0
1
(
C
I
:
5
4
.
9
6
–
6
1
.
0
0
)
5
8
.
0
7
7
6
.
4
0
(
C
I
:
5
5
.
7
–
6
0
.
4
4
)
5
3
.
4
1
7
8
.
1
0
(
C
I
:
5
0
.
4
1
–
5
6
.
4
1
)
5
1
.
2
0
7
8
.
0
8
*
(
C
I
:
4
8
.
2
1
–
5
4
.
1
9
)
L
D
L
-
C
(
m
g
d
l
 
1
)
1
3
1
.
1
5
7
1
4
.
5
1
(
C
I
:
1
2
5
–
6
8
–
1
3
6
.
6
2
)
1
3
3
.
5
6
7
1
9
.
1
0
(
C
I
:
1
2
6
.
3
6
–
1
4
0
.
7
6
)
1
3
2
.
3
1
7
1
9
.
2
4
(
C
I
:
1
2
5
.
0
5
–
1
3
9
.
5
7
)
1
3
0
.
9
1
7
1
5
.
1
0
(
C
I
:
1
2
5
.
3
2
–
1
3
6
.
5
0
)
1
4
9
.
8
7
1
7
.
1
8
*
(
C
I
:
1
4
3
.
4
4
–
1
5
6
.
1
6
)
1
5
2
.
8
1
7
1
8
.
1
2
*
*
#
(
C
I
:
1
4
6
.
1
0
–
1
5
9
.
5
2
)
T
G
(
m
g
d
l
 
1
)
1
2
4
.
8
7
7
4
6
.
1
(
C
I
:
1
0
7
.
4
8
–
1
4
2
.
2
6
)
1
1
9
.
3
0
7
4
7
.
8
1
(
C
I
:
1
0
1
.
2
7
–
1
3
7
.
3
3
)
1
2
7
.
6
3
7
4
0
.
6
0
(
C
I
:
1
1
2
.
3
2
–
1
4
2
.
9
4
)
1
2
4
.
1
1
7
5
8
.
2
7
(
C
I
:
1
0
2
.
5
3
–
1
4
5
.
6
9
)
1
0
7
.
2
1
7
6
4
.
3
0
*
(
C
I
:
8
3
.
3
9
–
1
3
1
.
0
3
)
1
0
1
.
0
4
7
4
3
.
6
5
*
*
(
C
I
:
8
4
.
8
7
–
1
1
7
.
2
1
)
C
I
¼
c
o
n
f
i
d
e
n
c
e
i
n
t
e
r
v
a
l
;
H
D
L
-
C
¼
h
i
g
h
-
d
e
n
s
i
t
y
l
i
p
o
p
r
o
t
e
i
n
c
h
o
l
e
s
t
e
r
o
l
;
L
D
L
-
C
¼
l
o
w
-
d
e
n
s
i
t
y
l
i
p
o
p
r
o
t
e
i
n
c
h
o
l
e
s
t
e
r
o
l
;
T
C
¼
t
o
t
a
l
c
h
o
l
e
s
t
e
r
o
l
;
T
G
¼
t
o
t
a
l
t
r
i
g
l
y
c
e
r
i
d
e
s
.
*
P
o
0
.
0
5
,
*
*
P
o
0
.
0
1
v
s
b
a
s
e
l
i
n
e
v
a
l
u
e
s
;
#
P
o
0
.
0
5
b
e
t
w
e
e
n
g
r
o
u
p
s
.
Exemestane and body composition
G Francini et al
156
British Journal of Cancer (2006) 95(2), 153–158 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
streated with exemestane: this finding may seem to differ from
those of other studies indicating that exemestane has a neutral
effect on LDL-C, but it must be remembered that our patients had
been treated with tamoxifen for at least 2 years, which markedly
reduces LDL-C levels (Love et al, 1990; Atalay et al, 2004; Esteva
and Hortobagyi, 2006; Markopoulos et al, 2005). The increase in
LDL-C may therefore be at least partially explained by the loss of
the positive action of tamoxifen. The decrease in HDL-C in the
exemestane group is in line with previous studies, and may be
explained by a direct action of exemestane and/or by the
interruption of tamoxifen therapy (Atalay et al, 2004; Lonning
et al, 2005; Markopoulos et al, 2005; Esteva and Hortobagyi, 2006).
The Intergroup Exemestane Study found a trend toward more
frequent myocardial infarction in patients treated with exemestane
than in those treated with tamoxifen (Coombes et al, 2004). We
found that 1-year’s use of exemestane led to more changes in
cholesterol parameters, which are commonly associated with an
increased risk of coronary heart disease (Table 3), thus indicating
that the lipid profiles of patients receiving exemestane or other
aromatase inhibitors should be monitored. However, it must be
borne in mind that the genesis of cardiovascular diseases is
multifactorial, and many authors have found that exemestane
treatment significantly reduces triglyceride levels, which may help
to balance the negative effect of the decrease in HDL-C (Atalay
et al, 2004; Markopoulos et al, 2005). Only large-scale randomised
trials and a long follow-up can answer the question as to whether
postmenopausal women treated with exemestane or other
aromatase inhibitors for 3–5 years are at greater cardiovascular
risk than those treated with tamoxifen.
In conclusion, the results of our study suggest that adjuvant
exemestane treatment may have an advantage over adjuvant
tamoxifen treatment in terms of body composition. In addition
to recent findings that the use of exemestane after 2–3 years
of tamoxifen therapy significantly improves disease-free survival
in comparison with standard 5-year tamoxifen treatment, this
could be a further factor worth considering when deciding on
adjuvant hormonal therapy for postmenopausal women with
breast cancer.
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